This is the hover veil
Menu
Menu
Home
COVID-19
MPX
About the taskforce
About the guidelines
FAQs
News
Taskforce TV
Contact us
COVID-19
MPX
About the taskforce
About the guidelines
FAQs
News
Taskforce TV
Contact us
News
News
Communique
Video
Explainer
Media release
Topics
Abatacept
Aboriginal and Torres Strait Islander people
ACEIs/ARBs
ACEM
ACIPC
ACNN
Acute and Critical Care Panel
Adults
AHPA
Alex Poole
Alistair Miller
Allied Health Professions Australia
Amanda Gwee
Anakinra
Angiotensin 2 receptor agonist (C21)
Annie Synnot
Antenatal corticosteroids
Antibiotics
Anticoagulants
Anticoagulation
Antivirals
ANZ Guidelines
ANZICS
ANZJOG
ANZPID COVID-19 Clinical Reference Group
Apixaban
Aprepitant
ARC
ASCOT
ASHM
ASID
Aspirin
ATAGI
Australasian Sleep Association
Australia Day honours
Australia Day Honours List
Australian and New Zealand Society for Geriatric Medicine
Australian College of Midwives
Australian Commission on Safety and Quality in Health Care
Australian Living Evidence Consortium (ALEC)
Azithromycin
Baloxavir marboxil
Bamlanivimab
Bamlanivimab plus etesevimab
Baricitinib
Basic Life Support
Bebtelovimab
BESSI principles
Breastfeeding
Bromhexine hydrochloride
Budesonide
Burnet
Camostat mesilate
Canakinumab
Cardiac arrest
Cardiac Arrest Working Group
Cardiopulmonary resuscitation guidance
Care after COVID-19
Care after COVID-19 flowchart
Care of Children
Care of Older People and Palliative Care Panel
Caroline Homer
Casirivimab plus imdevimab (Ronapreve)
CD24c
CENA
Chemophrophylaxis
Chemoprophylaxis Panel
CHF
Children and adolescents
Chloroquine
Ciclesonide
Clinical flowcharts
CMCS
Cochrane Australia
Colchicine
COMET-ICE
Commonwealth Department of Health and Aged Care
Conditional recommendation
Consumer Panel
Consumer-centered care
Convalescent plasma
Corticosteroids
Corticosteroids (Inhaled)
COVID-19
COVID-19 COS
CPAP/HFNO
CPR
CPR Flowcharts
Critical Disease Panel
CT-P59 monoclonal antibody
Darunavir-cobicistat
Decision Tool
Definitions of disease severity
Definitions of disease severity and risk of disease
Delayed umbilical cord clamping
Dexamethasone
Disease-modifying treatments
DMTC Panel
Drug treatments
Drug treatments flowcharts
Drug Treatments Panel
Dutasteride
ECMO
Enisamium
Ensovibep
Episode 6
Equity Trustees
Expert Advisory Group
Extracorporeal membrane oxygenation
Eye protection
Face masks
Facebook
FAQs
Favipiravir
Flowchart
GIN
Global Commission on Evidence
Good practice statements
GPs
Guideline Leadership Group
Guidelines Leadership Group
HCW
High-flow nasal oxygen
Hospital and Acute Care Panel
Hydroxychloroquine
Hydroxychloroquine plus azithromycin
Hyperbaric oxygen therapy
Ian Potter Foundation
ICEG
Imatinib
Immunodulatory treatments table
Immunoglobulin
Immunoglobulin plus methylprednisolone
Immunosuppressed
Infection Control Expert Group (ICEG)
Infection Control Matters Podcast
Infection Prevention and Control (IPC) Panel
Infliximab
Interferon beta-1a
Interferon Gamma
Interferon β-1a (inhaled)
International Women's Day
Intravenous immunoglobulin
IPC
Ivermectin
Jason Roberts
Joanne Muller
Lancet
Leadership
Lenzilumab
Living Evidence
Long COVID
Lopinavir-ritonavir
Lorraine Anderson
Magnesium Sulfate
Management of cardiac arrest
Mark Morgan
Methods Advisor
Methods Chair
Michelle King
Mild COVID-19
MJA
Molnupiravir (Lagverio)
Monkeypox (MPX)
Monoclonal antibodies
Monoclonal antibody therapy
MPX
MPX Panel
Murray PHN
N-acetylcysteine
Naltrexone
National Clinical Evidence Taskforce
NCET
NCIRS
Neonatal
Neonates
New England Journal of Medicine
New Topics & Questions
NHMRC
NICE
Nicole Allard
Nirmatrelvir plus ritonavir (Paxlovid)
Non-invasive ventilation
NPS MedicineWise
Nutrition
Observational Data Working Group
Oestrogen containing therapies
Opaganib
Oral antivirals
P2/N95 respirators
Paediatric & Adolescent Care
Paediatric & Adolescent Care Panel
Paediatric and Adolescent Care
Paediatric Decision Tool
Paediatric Management
Paediatrics
Pain management
Palliative and Aged Care Panel
Palliative Care
Palliative Care Working Group
PANORAMIC
Pathways to Care
Paxlovid prescribing guide
Paxlovid rebound
Peginterferon lambda
Penny Burns
Personal Protective Equipment (PPE)
Peter Morley
PIMS-TS
Podcast
Post-acute COVID-19
Post-COVID-19
post-exposure prophylaxis
Post-viral symptoms
Postnatal
pre-exposure prophylaxis
Pregnancy and perinatal care
Pregnancy and Perinatal Panel
Pregnant & Postpartum women
Pregnant or breastfeeding women
Primary and Chronic Care Panel
Prone positioning
Proxalutimide
Psychosocial support
Pulse oximeters
Puspa Sherlock
RACGP
RANZCOG
RCTs
Rebecca Randall
RECOVERY Trial
Regdanvimab (Regkirona)
Regeneron
REMAP-CAP
Remdesivir (Veklury)
Respiratory
Respiratory management
Respiratory support
Risk classification tool
RMSANZ
Royal Australian College of Surgeons
Rural and remote care
Ruxolitinib
Sabizabulin
Samantha Chakraborty
Sarilumab
Senior Clinical Fellow
Senior Evidence Officer
severe-critical COVID-19
Simon Craig
Skin and wound care
SMS notifications
Sofosbuvir plus daclatasvir
Sotrovimab
Sotrovimab (Xevudy)
Special populations
Steering Committee
Steroids
Steve McGloughlin
subcutaneous casirivimab plus imdevimab
Subscription
Tari Turner
Taskforce funding update
TaskforceTV
Team Profile
Tecovirimat
Telmisartan
TGA
THANZ
The Alfred
The Conversation
Thromboembolism
Timing of surgery
Tixagevimab plus cilgavimab (Evusheld)
Tocilizumab
Tofacitinib
Tracheostomy
Treatment
TSANZ
Umifenovir
Unvaccinated
Vaccination
Vaccine
Vaccinia immune globulin (VIG)
Venous thromboembolism (VTE) prophylaxis
Videolaryngoscopy
Vitamin C
Vitamin D
VTE prophylaxis
Webinar
Zinc
Featured
COVID-19 Research Pipeline
STUDIES
Cochrane COVID-19 Study Register
205,745
Registered/ Published
RCT
s
covid-nma.com
4,597
Registered
780
Published
SYSTEMATIC REVIEWS
Prospero
7,632
Registered
As at 24 March 2023
Tweets by evidence_aus
FILTERED BY > Cochrane Australia
Clear filter
National Clinical Evidence Taskforce Funding Update
15 December, 2022
Earlier this week the National Clinical Evidence Taskforce was informed that the Commonwealth Department of Health and Aged Care will not be continuing our contract to develop clinical guidelines for COVID-19 beyond December 31, 2022. As a collaboration of 35 member organisations, we are extremely proud of our shared work over the last 33 months to ensure Australian clinicians have...
News
Communique #73
27 October, 2022
Click for latest news:
Communique
Communique #70
17 August, 2022
Click for the latest Taskforce news:
Communique
Meet the Evidence Team: Annie Synnot
5 August, 2022
Read our Q&A with Annie Synnot, Consumer Panel Methods Chair: Introduce yourself and your role with the Taskforce/Consumer Panel. Hi, I’m Annie Synnot and I’m based in Adelaide....
News
Communique #58
18 February, 2022
Click for the latest Taskforce news:
Communique
Communique #51
15 October, 2021
WEEK IN REVIEW Updates to the Living Treatment Guidelines New recommendations New recommendation for Continuous positive airway pressure / High-flow nasal oxygen therapy The Hospital and Acute Care...
Communique
Communique #50
29 September, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Seven new treatment recommendations for pregnant and breastfeeding women Sotrovimab for pregnant women Following recent recommendations for the...
Communique
Communique #49
26 August, 2021
WEEK IN REVIEW Taskforce makes new conditional recommendation for sotrovimab The Taskforce today published three recommendations on the use of sotrovimab for the treatment of COVID-19 in adults...
Communique
Coverage: Understanding evidence
17 August, 2021
Science reporter for the The Age and Sydney Morning Herald, Liam Mannix explains the critical role of gold standard evidence and highlights the role of Cochrane and the...
News
Communique #45
3 June, 2021
Dear colleagues, On behalf of our 32 Taskforce members, we acknowledge our Victorian colleagues during another challenging and anxious time. Look after yourselves and each other, and we all hope an easing of...
Communique
Communique #42
22 April, 2021
Message from the Chair and Executive Director Dear Colleagues We’ve just passed 12-months since the first publication of the Australian clinical guidelines for the care of people with COVID-19....
Communique
Communique #41
1 April, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Convalescent plasma recommendation changed to 'do not use' The Taskforce Disease Modifying and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique
Communique #40
18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique
Communique #39
25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique
Communique #38
11 February, 2021
Message from the Taskforce Chair Dear colleagues As we enter the second year of the COVID-19 pandemic it is timely to acknowledge the important role of the Taskforce’s...
Communique
Communique #37
29 January, 2021
Following a well-earned break, the Taskforce team has now returned to full capacity. Global evidence surveillance continued throughout January, with six clinical panel meetings held since January 11....
Communique
Weekly Communique #36
17 December, 2020
Dear colleagues, It’s hard to fully comprehend a year like 2020. The pandemic has affected us all and no doubt its impact will continue and reverberate for some...
Communique
Weekly Communique #35
10 December, 2020
WEEK IN REVIEW Updates to the living guideline New recommendations published this week cover: Combined metabolic cofactor supplementation (CMCS) Vitamin D analogues (formerly just calcifediol, now also includes cholecalciferol) Updated...
Communique
Weekly Communique #33
26 November, 2020
WEEK IN REVIEW Updates to the living guideline Three new recommendations have been published this week covering: Bamlanivimab Fluvoxamine Intravenous immunoglobulin VTE prophylaxis for children and adolescents Further details are...
Communique
Weekly Communique #31
12 November, 2020
WEEK IN REVIEW IPC Panel EOI for paediatric and clinical engineering expertise The Taskforce is calling for Expressions of Interest from suitably qualified individuals with paediatric or clinical...
Communique
Weekly Communique #30
5 November, 2020
WEEK IN REVIEW Bromhexine hydrochloride added to list of 'only in clinical trials' The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed two new trial results for bromhexine hydrochloride (commonly...
Communique
Weekly Communique #29
29 October, 2020
WEEK IN REVIEW Updates to the living guideline this week New recommendations Three new recommendations have been published covering: Triazavirin Other immunomodulatory agents (PIMS-TS) Aspirin and antithrombotic agents...
Communique
Weekly Communique #28
22 October, 2020
WEEK IN REVIEW SAVING LIVES SAFELY: New CPR flowcharts published today The Taskforce, in partnership with the Infection Control Expert Group (ICEG), has published new clinical flowcharts to guide clinicians...
Communique
Weekly Communique #27
15 October, 2020
WEEK IN REVIEW New PIMS-TS recommendations The Taskforce has made two new consensus recommendations for the management of children with suspected or confirmed Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2...
Communique
Weekly Communique #26
8 October, 2020
With our evidence team and panels taking a much-needed break, a smaller edition today with no new recommendations or updates to the guidelines and flowcharts this week. Our next update will be next Thursday,...
Communique
Weekly Communique #12
2 July, 2020
WEEK IN REVIEW Taskforce makes first recommendation on Dexamethasone The Taskforce has made two conditional recommendations on the use of dexamethasone in treatment of patients with COVID-19: Consider...
Communique
Weekly Communique #7
28 May, 2020
WEEK IN REVIEW The Taskforce has issued a consensus recommendation to consider increased-dose venous thromboembolism (VTE) prophylaxis for adults with severe to critical COVID-19. This recommendation was developed with input from thrombosis specialists on the Taskforce's...
Communique
Weekly Communique #5
14 May, 2020
TASKFORCE UPDATE This week we welcomed the Australian and New Zealand Society for Geriatric Medicine as a new member of the Taskforce. Two new expert guideline panels have...
Communique
